Code of Federal Regulations · Section
§ 312.86 — Focused Fda Regulatory Research
21 C.F.R. § 312.86
View:
At the discretion of the agency, FDA may undertake focused regulatory research on critical rate-limiting aspects of the preclinical, chemical/manufacturing, and clinical phases of drug development and evaluation. When initiated, FDA will undertake such research efforts as a means for meeting a public health need in facilitating the development of therapies to treat life-threatening or severely debilitating illnesses.
Authorizing Statute
-
Adulterated drugs and devices21 U.S.C. § 351
-
Regulation of biological products42 U.S.C. § 262
-
Definitions; generally21 U.S.C. § 321